[Diabetic nephropathy: emerging treatments], PMID: 24938412
Antibodies to watch in 2020, PMID: 31847708
Antibody-based therapies for idiopathic pulmonary fibrosis, PMID: 32098521
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis, PMID: 28610597
Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells, PMID: 24204045
Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury, PMID: 32227398
Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy, PMID: 32379362
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis, PMID: 31811619
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer, PMID: 26575166
Connective Tissue Growth Factor Is a Novel Prodepressant, PMID: 29861095
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model, PMID: 29719620
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, PMID: 23836645
CTGF is a therapeutic target for metastatic melanoma, PMID: 23435419
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β, PMID: 30716392
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis, PMID: 28376190
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis, PMID: 26965296
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition, PMID: 27059922
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies, PMID: 26156092
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer, PMID: 32817130
Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis, PMID: 28710437
Molecular targets for treatment of kidney fibrosis, PMID: 23179685
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011, PMID: 21386633
Novel agents in the treatment of pancreatic adenocarcinoma, PMID: 23474556
Novel therapies for diabetic kidney disease, PMID: 24602462
Onkologie und Versorgung in Fach- und Publikumsmedien: Antikörper Pamrevlumab bei radiogen induzierter Lungenfibrose? L-Carnitin und Omega-3-Fettsäuren zur Verhinderung von Kardiotoxizität durch Anthrazykline? Krebsrisiko bei Nachkommen nach Kinderwunschbehandlung? Tumormarker CA 50 beim Pankreaskarzinom – noch relevant? Immunschwäche nach Krebstherapie?, PMID: 33173255
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis, PMID: 32447983
Pamrevlumab in idiopathic pulmonary fibrosis, PMID: 31575507
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial, PMID: 31575509
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria, PMID: 20522536
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity, PMID: 30400950
Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab, PMID: 29347981
Surgical strategies and novel therapies for locally advanced pancreatic cancer, PMID: 28513899
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, PMID: 33054319
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth, PMID: 24154679
Treatment of Renal Fibrosis-Turning Challenges into Opportunities, PMID: 28284377
Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. [DHD82301]
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462
Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab., PMID:40355288
"Regression to the truth": lessons learned from negative IPF trials., PMID:40255293
The latest developments in synthetic approaches to Duchenne muscular dystrophy., PMID:39899275
The case of Connective Tissue Growth Factor (CTGF) and the pit of misleading and improper nomenclatures., PMID:39712858
ER stress-induced YAP upregulation leads to chondrocyte phenotype loss in age-related osteoarthritis., PMID:39600372
Evidence from recent clinical trials in fibrotic interstitial lung diseases., PMID:39114938
The future of clinical trials in idiopathic pulmonary fibrosis., PMID:38963152
When the Third Time Is Not the Charm-Trial Outcomes in Idiopathic Pulmonary Fibrosis., PMID:38762799
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial., PMID:38762797
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials., PMID:38281037
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond., PMID:37953604
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis., PMID:37797203
Blocking CCN2 Reduces Established Palmar Neuromuscular Fibrosis and Improves Function Following Repetitive Overuse Injury., PMID:37762168
Blocking CCN2 Reduces Established Bone Loss Induced by Prolonged Intense Loading by Increasing Osteoblast Activity in Rats., PMID:37701153
A randomized trial of pamrevlumab in patients with COVID-19 pneumonia., PMID:37605035
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy., PMID:37248912
CTGF as a multifunctional molecule for cartilage and a potential drug for osteoarthritis., PMID:36325449
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis., PMID:35145039
Connective-Tissue Growth Factor Contributes to TGF-β1-induced Lung Fibrosis., PMID:34797990
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity., PMID:33358571
[Not Available]., PMID:33173255
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis., PMID:33054319
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer., PMID:32817130
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis., PMID:32447983
Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy., PMID:32379362
Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury., PMID:32227398
Antibody-based therapies for idiopathic pulmonary fibrosis., PMID:32098521
Antibodies to watch in 2020., PMID:31847708
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis., PMID:31811619
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial., PMID:31575509
Pamrevlumab in idiopathic pulmonary fibrosis., PMID:31575507
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β., PMID:30716392
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity., PMID:30400950
Connective Tissue Growth Factor Is a Novel Prodepressant., PMID:29861095
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model., PMID:29719620
Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab., PMID:29347981
Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis., PMID:28710437
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis., PMID:28610597
Surgical strategies and novel therapies for locally advanced pancreatic cancer., PMID:28513899
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis., PMID:28376190
Treatment of Renal Fibrosis-Turning Challenges into Opportunities., PMID:28284377
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition., PMID:27059922
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis., PMID:26965296
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer., PMID:26575166
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies., PMID:26156092
[Diabetic nephropathy: emerging treatments]., PMID:24938412
Novel therapies for diabetic kidney disease., PMID:24602462
Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells., PMID:24204045
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth., PMID:24154679
For research use only. Not for human or drug use.
